Pittsburgh Compound-B and Alzheimer’s Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study
M. Degerman Gunnarsson(Uppsala University), Lena Kilander(British Geriatrics Society), Maria Lindau(Stockholm University), Taher Darreh‐Shori(Karolinska University Hospital), Soumen Basu(Thapar Institute of Engineering & Technology), Agneta Nordberg(Karolinska Institutet), Hans Basun(Uppsala University), A Larsson(Uppsala University Hospital), Lars Lannfelt(BioArctic Neuroscience (Sweden)), A. Wall(General Electric (Spain)), Kaj Blennow(Sahlgrenska University Hospital)
Cited by 33
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k